Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05040178 · ClinicalTrials.gov registry record

An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

A clinical trial of Methylmalonic Acidemia and Propionic Acidemia, sponsored by Recordati Group.

Recruiting
Registry status
20
Enrollment target
5
Study locations

NCT05040178 is a study of Methylmalonic Acidemia and Propionic Acidemia that is actively recruiting participants, run by Recordati Group. The registered enrollment target is 20 participants, below the 424-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05040178, a study of Methylmalonic Acidemia and Propionic Acidemia, is actively recruiting participants, sponsored by Recordati Group.

RECRUITING
Registry status
20 participants
Enrollment target
5
Study locations

Study Summary

To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.

Interventions

  • DRUG Carglumic Acid

Study Locations (5)

District of Columbia

  • Children's National Hospital - Washington D.C.

Florida

  • University of South Florida - Tampa

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Indiana

  • Riley Children's Hospital - Indianapolis

New York

  • Icahn School of Medicine at Mt. Sinai - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-06-30
Est. Completion 2032-06-30

Sponsor

Recordati Group

11 total trials

What the Registry Record Tells You About NCT05040178

The ClinicalTrials.gov registry entry for NCT05040178 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 424-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (95% lower). The listed sponsor is Recordati Group, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Methylmalonic Acidemia appearing as the primary indexed condition, and to 1 intervention - of which Carglumic Acid is the first listed.

NCT05040178 reports 5 study locations spanning 5 distinct geographic areas - top geographies include District of Columbia, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT05040178 about?

NCT05040178 is a clinical study titled "An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics". To obtain short-term and long-term clinical safety information, in pediatric and adult patients with PA and MMA treated with Carbaglu®.

What is the current status of trial NCT05040178?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2022-06-30. Estimated completion is 2032-06-30.

What conditions does trial NCT05040178 study?

This clinical trial studies the following conditions: Methylmalonic Acidemia, Propionic Acidemia, Hyperammonemia.

What interventions are being tested in trial NCT05040178?

The interventions under investigation include: Carglumic Acid (DRUG).

Who is sponsoring clinical trial NCT05040178?

This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05040178 being conducted?

This trial has 5 study locations across District of Columbia, Florida, Illinois, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Methylmalonic Acidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.